New Gout Drug: this caregiver-focused guide explains what new gout drug means in plain English, the day-to-day implications for families, and when to bring it up with a clinician. If you arrived here looking for a quick orientation on new gout drug, the table of contents below points to the section you need; the full guide picks up after it.
For a broader overview, see our dementia treatment and medications guide.
Table of contents
- Table of Contents
- What Is the New Gout Drug Awaiting FDA Approval, and Why Did It Take So Long?
- How NASP Performed in Phase 3 Clinical Trials
- How NASP Compares to Krystexxa, the Only Current Biologic for Refractory Gout
- What Other Gout Drugs Are in the Pipeline for 2026 and Beyond
- Why Gout Matters for Brain Health and Dementia Risk
- Navigating Treatment Decisions as a Caregiver
- What to Expect in the Next Year for Gout Treatment
After years of limited options for patients with severe, treatment-resistant gout, a new biologic therapy called NASP is on the verge of FDA approval, with a decision expected by June 27, 2026. Developed by Swedish Orphan Biovitrum (Sobi), NASP represents the first major advance in refractory gout treatment since Krystexxa (pegloticase) came to market over a decade ago. For the millions of Americans living with gout that refuses to respond to standard medications like allopurinol or febuxostat, the wait may finally be nearing its end.
This matters beyond joint pain alone. Chronic gout is increasingly recognized as a systemic inflammatory condition with links to cardiovascular disease, kidney damage, and emerging research into neuroinflammation. For readers of this site who follow brain health closely, the connection between persistent inflammatory states and cognitive decline makes gout treatment advances worth paying attention to. In this article, we will walk through what NASP actually is, how it performed in clinical trials, how it compares to existing treatments, and what other gout drugs are coming down the pipeline.
Table of Contents
- What Is the New Gout Drug Awaiting FDA Approval, and Why Did It Take So Long?
- How NASP Performed in Phase 3 Clinical Trials
- How NASP Compares to Krystexxa, the Only Current Biologic for Refractory Gout
- What Other Gout Drugs Are in the Pipeline for 2026 and Beyond
- Why Gout Matters for Brain Health and Dementia Risk
- Navigating Treatment Decisions as a Caregiver
- What to Expect in the Next Year for Gout Treatment
- Conclusion
- Frequently Asked Questions
What Is the New Gout Drug Awaiting FDA Approval, and Why Did It Take So Long?
NASP, formerly known as SEL-212, is a two-component intravenous infusion administered every four weeks. The first component, called NAS, is a nanoencapsulated form of sirolimus designed to suppress the body’s tendency to form anti-drug antibodies. The second component, pegadricase, is a uricase enzyme that directly breaks down uric acid in the bloodstream. This combination approach tackles a problem that has plagued earlier biologic gout treatments: the immune system attacking the drug before it can finish its work. The FDA granted NASP Fast Track designation in May 2024, acknowledging the serious unmet medical need in refractory gout.
Sobi initiated a rolling Biologics License Application on July 2, 2024, and the FDA accepted it, setting a PDUFA target action date of June 27, 2026. The lengthy timeline reflects the rigorous process of biologics review, not unusual for a novel two-component therapy. For patients who have suffered through years of debilitating flares and joint destruction, however, every month of waiting feels interminable. To put the timeline in perspective, the last notable gout-related FDA approval in the United States was Gloperba, a colchicine oral solution approved in August 2024 for preventing gout flares. That was not a new molecule but rather a reformulation of one of the oldest drugs in medicine. A truly novel mechanism of action for gout has not received FDA approval in years, which is why NASP has attracted so much attention from both rheumatologists and patients.
How NASP Performed in Phase 3 Clinical Trials
The pivotal evidence for NASP comes from two Phase 3 trials, DISSOLVE I and DISSOLVE II. Both studies met their primary endpoint, which required patients to achieve and maintain serum uric acid levels below 6 mg/dL for at least 80 percent of the time during the sixth month of treatment. Pooled across both studies, response rates were 51 percent at the higher dose and 43 percent at the lower dose. While those numbers may not sound overwhelming at first glance, they are significant for a patient population that has already failed every other available therapy. However, it is important to understand what these numbers mean in practice. A 51 percent response rate means that roughly half of patients receiving the high dose achieved sustained uric acid control.
For the other half, the drug did not maintain adequate suppression. This is not a cure-all, and patients considering NASP, if approved, should have realistic expectations. Refractory gout is notoriously difficult to treat, and even partial response rates in this population represent meaningful clinical progress compared to the alternative of continued joint destruction and tophi formation. There is also the matter of administration. NASP is an intravenous infusion given every four weeks, which means regular clinic visits. For elderly patients or those with mobility challenges, particularly individuals who may also be managing cognitive decline or dementia caregiving responsibilities, the logistics of monthly infusion appointments are a real consideration that should be discussed with a care team.
How NASP Compares to Krystexxa, the Only Current Biologic for Refractory Gout
If approved, NASP would directly compete with Krystexxa (pegloticase), manufactured by Amgen, which is currently the only FDA-approved biologic for chronic refractory gout. Krystexxa works by a similar uricase mechanism, breaking down uric acid enzymatically. But it has a well-documented weakness: a high rate of anti-drug antibody formation that can neutralize the treatment and increase the risk of infusion reactions. This is exactly the problem NASP was designed to solve. By pairing the uricase enzyme with nanoencapsulated sirolimus, NASP aims to suppress the antibody response that undermines Krystexxa’s effectiveness.
In clinical practice, rheumatologists have tried combining Krystexxa with immunosuppressants like methotrexate to reduce antibody formation, an off-label workaround that has shown some benefit but adds complexity and side effects. NASP builds the immunomodulation directly into the treatment regimen. For patients and caregivers weighing their options, the practical difference comes down to durability of response. If NASP can maintain uric acid suppression over longer periods without the antibody dropout seen with Krystexxa alone, it could meaningfully change outcomes for people living with the most severe form of gout. That said, until post-approval real-world data becomes available, head-to-head comparisons remain somewhat theoretical.
What Other Gout Drugs Are in the Pipeline for 2026 and Beyond
NASP is not the only gout drug in development. Several other therapies are working through clinical trials, each targeting a different aspect of the disease. Dapansutrile, for instance, targets the NLRP3 inflammasome to inhibit IL-1β production, addressing the acute inflammatory response that causes gout flares rather than lowering uric acid itself. It is forecasted for a potential launch as early as 2026, though the exact timeline remains uncertain. On the uric acid-lowering front, Arthrosi Therapeutics has been developing pozdeutinurad, a URAT1 inhibitor that promotes uric acid excretion through the kidneys.
The company raised 153 million dollars to advance this drug, and two Phase 3 trials are fully enrolled with results expected in the second quarter of 2026. Meanwhile, Eisai’s dotinurad, marketed as URECE, has already been approved in China in December 2024, Thailand in September 2024, and the Philippines in February 2025 for gout with hyperuricemia. It has not yet been approved in the United States. The tradeoff between these different approaches matters. A drug like NASP is designed for the sickest patients who have failed everything else, while a URAT1 inhibitor like pozdeutinurad could potentially serve a broader population of gout patients who need better uric acid management but are not yet in the refractory category. Patients and their physicians will eventually need to consider where on the disease spectrum they fall when choosing among these options, assuming multiple new treatments reach the market.
Why Gout Matters for Brain Health and Dementia Risk
This may seem like an unusual topic for a brain health website, but the connection between chronic gout and neurological outcomes is more relevant than many people realize. Gout is fundamentally a disease of chronic inflammation, and sustained systemic inflammation is one of the recognized risk factors for cognitive decline and dementia. Elevated uric acid levels have a complicated relationship with brain health, with some research suggesting uric acid may have antioxidant properties that protect neurons, while other studies link hyperuricemia to vascular damage that harms the brain. For older adults managing both gout and early cognitive changes, the burden of uncontrolled gout extends beyond joint pain. Repeated flares disrupt sleep, limit physical activity, and increase reliance on medications that carry their own cognitive side effects.
Colchicine can cause gastrointestinal distress that leads to poor nutrition. Corticosteroids used during acute flares can cause confusion and agitation in older adults, effects sometimes mistaken for worsening dementia. A word of caution: no one should interpret a new gout drug as a dementia treatment. The link between inflammatory control and brain health is real but indirect. What matters practically is that better gout management, through whatever medication works, removes one source of chronic inflammation and physical suffering that can compound cognitive vulnerability in aging adults.
Navigating Treatment Decisions as a Caregiver
For family caregivers helping a loved one manage both gout and cognitive decline, treatment decisions can feel overwhelming. Consider the case of someone caring for a parent with moderate dementia who also has refractory gout. Monthly infusion visits for a drug like NASP, if approved, would mean arranging transportation, managing the patient during a clinical setting they may find disorienting, and monitoring for side effects that the patient may not be able to articulate clearly.
These logistics are not reasons to avoid effective treatment, but they are reasons to plan carefully. Caregivers should work with both the rheumatologist and the primary care physician or neurologist to coordinate scheduling and to establish clear protocols for what to watch for after infusion appointments. Having a written plan in simple language can help when the caregiver is not the only person assisting with the patient’s care.
What to Expect in the Next Year for Gout Treatment
The next twelve months could reshape the gout treatment landscape more than any period in the past decade. The FDA decision on NASP, expected by June 27, 2026, is the most immediate milestone. If approved, it would be the first new biologic mechanism for refractory gout in years. Close behind, Phase 3 results for Arthrosi’s pozdeutinurad are expected in the second quarter of 2026, which could open another front in uric acid management for a broader patient population.
None of this is guaranteed. FDA approvals can be delayed by requests for additional data, manufacturing concerns, or safety signals that emerge during review. But the direction of travel is encouraging. After a long period in which gout received relatively little pharmaceutical attention compared to other inflammatory conditions, multiple serious efforts are converging at once. For patients and caregivers who have been managing this disease with limited and imperfect tools, that convergence is worth watching closely.
Conclusion
The gout treatment pipeline is more active now than it has been in years. NASP, the most advanced candidate, could receive FDA approval by late June 2026, offering a new option for patients with chronic refractory gout who have exhausted standard therapies. Meanwhile, other drugs targeting different mechanisms, from NLRP3 inflammasome inhibition to novel URAT1 inhibitors, are progressing through trials and international approvals.
For readers focused on brain health and dementia care, the relevance is twofold. Better gout management reduces a source of chronic inflammation that may contribute to cognitive decline over time. And for caregivers helping loved ones navigate both conditions, understanding what new treatments are coming helps with planning and advocacy. Talk to your loved one’s rheumatologist about whether current treatment is adequately controlling uric acid, and ask whether emerging therapies might be appropriate when they become available.
Frequently Asked Questions
Has a new gout drug been FDA-approved in 2026?
As of March 2026, no completely new gout drug has been FDA-approved. The most anticipated approval is NASP by Sobi, with an FDA decision expected by June 27, 2026. The last notable gout-related approval was Gloperba, a colchicine oral solution, in August 2024.
What is NASP and how does it work?
NASP is a two-component IV infusion given every four weeks. It combines nanoencapsulated sirolimus, which prevents the body from forming anti-drug antibodies, with pegadricase, a uricase enzyme that breaks down uric acid. It is designed for patients with chronic refractory gout who have not responded to standard treatments.
How effective was NASP in clinical trials?
In the DISSOLVE I and II Phase 3 trials, pooled response rates were 51 percent at the high dose and 43 percent at the low dose. The primary endpoint was maintaining serum uric acid below 6 mg/dL for at least 80 percent of the time during month six of treatment.
How is NASP different from Krystexxa?
Both use uricase enzymes to break down uric acid, but NASP includes a built-in immunomodulatory component to prevent anti-drug antibodies, which is a major limitation of Krystexxa. Krystexxa is currently the only FDA-approved biologic for refractory gout.
Can gout affect brain health or dementia risk?
Chronic gout involves sustained systemic inflammation, which is a recognized risk factor for cognitive decline. Additionally, the burden of uncontrolled gout, including disrupted sleep, reduced physical activity, and medication side effects, can compound cognitive vulnerability in older adults.
Are there other new gout drugs in development?
Yes. Dapansutrile targets the NLRP3 inflammasome and may launch as early as 2026. Arthrosi’s pozdeutinurad, a URAT1 inhibitor backed by 153 million dollars in funding, has Phase 3 results expected in Q2 2026. Eisai’s dotinurad has been approved in China, Thailand, and the Philippines but not yet in the US.
You Might Also Like
- New Lupus Drug Gets Approval — First of Its Kind in Years
- Epilepsy Drug Approved for Rare Genetic Condition — A Breakthrough for Patients
- Why Nerve Pain Is So Hard to Treat — And the New Approaches That Work
Sources used for this New Gout Drug guide
- National Institute on Aging — Alzheimer’s treatments
- FDA — Approved Drugs for Alzheimer’s
- Alzheimer’s Association — Medications for Memory
This article is informational and not medical advice. See our Editorial Policy for how we research and review content. Last reviewed June 6, 2026.
